My CEO Tenure
By
Joseph Paul

As the CEO of Skinny Genes Inc., Skinny Genes is searching for prospective investors to fund the company initiatives. Our company is a major competitor in the biotechnology field and we specialize in the research and development of therapeutic drugs, seeking to improve the quality of life of patients all around the world. Skinny Genes’ forte has been the ability to hire the most talented individuals while having high employee retention rates. Under my watch, Skinny Genes has recently acquired a license for a novel technology through an agreement with John Hopkins University. The license is for the technology and techniques involved in the process of regulating the TDP-43 protein. The TDP-43 protein has been known to regulate the Tbc1d1 gene, which is a gene that has been associated with human obesity. Skinny Genes is seeking potential investors to fund additional research and studies to develop a drug that can regulate the TDP-43 protein in a human system as a drug that can provide treatment for overweight and obese people, with a potential market that reaches all over the world. Company Background
Skinny Genes, Inc., founded in 2005, is a medical research company based in Bethesda, Maryland, specializing in developing therapeutic medicines to help improve the quality of life in people. Skinny Genes Inc.’s goal is to be able to develop a novel technology into a drug that is able combat obesity by targeting the genes that regulate the formation of fat cells. We offered the
Products and Services: Skinny Genes currently offers Humatrex, an injectable drug used to treat patients with type 2 diabetes mellitus. Skinny Genes does not offer any other products or services outside of this.
Technologies
Skinny Genes has a patent for recombinant DNA technique in using Escherichia coli to produce human insulin.
Markets
According to the United States Center for Disease Control (CDC), in 2010, more than 35% of adults and 17% of children and adolescents in the United States are considered clinically obese (CDC, 2012). The potential market size for any drugs targeting obese adults will be approximately 100 million in the US alone.

My second company as CEO is Janus. Janus, occupies the initial diffuse value chain space that both the basic science and the industry can not fill up. The basic science is not able to efficiently contrast the hypothesis, and the industry is commonly not interested if there is a lot to prove. To this end, we acquire exploration rights of academic discoveries or complex projects from third parties and outline a potential product or technology platform, defining a development strategy designed to cover, within two years, those deficiencies that prevent their development progression. Once the implementation planis defined, we manage its execution based on networking with external suppliers, and if the results support and strengthen the product profile, we seek partners (start-ups, established companies or venture capital) capable of completing the development stage and marketing the final product. Our company brings extensive experience in managing early stage applied biomedical projects in all its dimensions: operational, strategic and business development. We do not pretend to know the answers, but we are in a position to make the key questions to the appropriate partners. Like the Roman god Janus, in Janus Development SL, we want to be bridge and gate in biomedical knowledge that transforms economic and social value, with a sustainable business model to generate adequate returns for our investors. JANUS DEVELOPMENT´s final costumer are biotech and pharmaceutical companies which buy products at earlier stages of research (preclinical and clinical proof of concept), investing in clinical development in order to bring them to the market. In this sense, for each of the purchased licenses, JANUS conducts a specific market study, creating a detailed product profile, depending on both the selected pharmaceutical indication and the market competition in the defined indication. The study includes product market projections and sales expectations in their particular area. Moreover, JANUS key business opportunity is determined by the spanish technology generators which could deliver licensable projects in an important volume and excelence quality that allow to develop a portfolio of research projects attractive to the end customer.These three types of clients have in common the generation of potentially positive research results for society, but they lack the resources or expertise to analyze, select, strategically protect and develop the technologies generated. JANUS offers the possibility of developing their technologies, obtain future economic benefits, and fulfilling their moral goals of returning part of the value generated by their research to society.The JANUS business model is based on investment in research projects on which acquires licensing rights to obtain future income from sub-licensees thereof, distributing a percentage to the originators of the technology.
Occasionally JANUS use its skills to provide services to biotechnology and pharmaceutical companies, without making their own investment but charging a consultancy fee, waiving or reducing significantly their participation in future revenues from sublicenses. However, restricting the number of such projects to a maximum of 20% of operating capacity, in order to maintain a certain revenue stream that would prevent cash tensions, guarantee our in-house projects disability. | My third company is Genentech. Global consumers want faster acting medicines, bigger fruit, studier crops and all at a cheaper price. As CEO, these are some of the possibilities of biotechnology that will be offer under my watch . As scientists advanced their understanding in the various biological fields, they applied this knowledge to design new medicines, to grow pest resistant crops that produce higher yields, and to clean pollution without the use of harmful chemicals. The application of biological processes to solve problems and to make useful products is termed Biotechnology (Commonwealth Biotechnology Ministerial Council 2000). Genentech, credited as being the first biotech company (Genentech Home Page n.d.), was started in 1976. The company utilized recombinant DNA technology to produce medically valuable proteins reliably and efficiently. Biotechnology has been applied across many industries including health and medicine, agriculture, forestry and mining. So ubiquitous is the technology that it has become a new industry. In 2005 there were over 4000 biotech companies listed worldwide (Greenwood 2005); 200 biotech medicines were on the market with an estimated sales revenue of A$66.5 billion; and 80 million hectares of biotech crops were planted in 17 countries. These numbers suggest that the industrial application of biotechnology can result in commercially successful ventures. The industries capacity for innovation and generation of revenue and employment while meeting consumer needs has attracted the attention of governments worlwide It has the characteristics of a growth industry that countries are seeking to develop their local industries including Australia (Wells, Coady & Inge 2003).